Bevacizumab Progression-free Survival Benefit Upheld in AVEREL Trial - The ASCO Post
Impact of Bevacizumab-containing Primary Treatment on Outcome of Recurrent Ovarian Cancer: An Italian Study | Anticancer Research
Bevacizumab treatment for newly diagnosed glioblastoma: Systematic review and meta-analysis of clinical trials
Evidence for improved survival with bevacizumab treatment in recurrent high-grade gliomas: a retrospective study with (“pseudo-randomized”) treatment allocation by the health insurance provider | SpringerLink
IMpower150 Clinical Trial Results | TECENTRIQ® (atezolizumab)
FOLFOXIRI plus bevacizumab versus FOLFIRI plus bevacizumab as first-line treatment of patients with metastatic colorectal cancer: updated overall survival and molecular subgroup analyses of the open-label, phase 3 TRIBE study - The
Bevacizumab plus erlotinib versus erlotinib alone in Japanese patients with advanced, metastatic, EGFR-mutant non-small-cell lung cancer (NEJ026): overall survival analysis of an open-label, randomised, multicentre, phase 3 trial - The Lancet Respiratory
Role of front-line bevacizumab in advanced ovarian cancer: the OSCAR study | International Journal of Gynecologic Cancer
Adding Olaparib to Bevacizumab Maintenance Improves Progression
Avastin® (bevacizumab) Clinical Trials | MCRC Treatment
Improved Survival with Bevacizumab in Advanced Cervical Cancer | NEJM
Overall survival and time to treatment failure for patients eligible... | Download Scientific Diagram
When more is better: bevacizumab treatment for patients with ovarian cancer
Overall survival with chemotherapy involving bevacizumab in mcrc... | Download Scientific Diagram
Bevacizumab with 5-fluorouracil, leucovorin, and oxaliplatin versus bevacizumab with capecitabine and oxaliplatin for metastatic colorectal carcinoma: results of a large registry-based cohort analysis | BMC Cancer | Full Text
Servier and Taiho Oncology Present Overall Survival Data for Trifluridine/Tipiracil (LONSURF®) In Combination With Bevacizumab in Patients With Refractory Metastatic Colorectal Cancer at 2023 ASCO Gastrointestinal Cancers Symposium
Systemic administration of bevacizumab prolongs survival in an in vivo model of platinum pre-treated ovarian cancer
Bevacizumab plus fosbretabulin in recurrent ovarian cancer: Overall survival and exploratory analyses of a randomized phase II NRG oncology/gynecologic oncology group study - ScienceDirect
Bevacizumab and chemotherapy for recurrent glioblastoma | Neurology
Avastin® (bevacizumab) Clinical Trials | CC Treatment
Cancers | Free Full-Text | Bevacizumab in First-Line Chemotherapy Improves Progression-Free Survival for Advanced Ovarian Clear Cell Carcinoma
Overall survival for patients randomized to receive (A) bevacizumab (n... | Download Scientific Diagram
Bevacizumab in the Management of Epithelial Ovarian Cancer | touchONCOLOGY
Avastin® (bevacizumab) Clinical Trials for Ovarian Cancer | HCP
Partnering bevacizumab with irinotecan as first line-therapy of metastatic colorectal cancer improves progression free survival-A retrospective analysis | PLOS ONE
Efficacy of FOLFIRI plus cetuximab vs FOLFIRI plus bevacizumab in 1st-line treatment of older patients with RAS wild-type metastatic colorectal cancer: an analysis of the randomised trial FIRE-3 | British Journal of
Bevacizumab in First-line Therapy of Metastatic Colorectal Cancer: A Retrospective Comparison of FOLFIRI and XELIRI | Anticancer Research
Landmark OS for HCC, updated IMbrave150 data - Medical Conferences
